Vor Biopharma Inc. Depreciation
Vor Biopharma Inc. (VOR) reported Depreciation of $64.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- Vor Biopharma Inc. depreciation for the quarter ending 2026-06-30 was $36.00K, a 98.29% decline year-over-year.
- Vor Biopharma Inc. depreciation for the quarter ending 2026-03-31 was $28.00K, a 96.61% decline year-over-year.
- Vor Biopharma Inc. depreciation for the quarter ending 2025-12-31 was $23.00K, a 97.34% decline year-over-year.
- Vor Biopharma Inc. depreciation for the quarter ending 2025-09-30 was $2.00K, a 99.78% decline year-over-year.
- Vor Biopharma Inc. depreciation for fiscal 2025 was $2.89M, a 18.17% decline from fiscal 2024.
- Vor Biopharma Inc. depreciation for fiscal 2024 was $3.53M, a 1.03% increase from fiscal 2023.
- Vor Biopharma Inc. depreciation for fiscal 2023 was $3.49M, a 38.30% increase from fiscal 2022.
- Vor Biopharma Inc. depreciation for fiscal 2022 was $2.52M, a 76.08% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $64.00K 10-Q · filed 2026-08-11 | $87.00K derived: sum of 3 quarters · filed 2026-08-11 | $89.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $28.00K 10-Q · filed 2026-05-13 | $51.00K derived: sum of 2 quarters · filed 2026-05-13 | $53.00K derived: sum of 3 quarters · filed 2026-05-13 | $2.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $25.00K derived: sum of 2 quarters · filed 2026-03-30 | $2.13M derived: sum of 3 quarters · filed 2026-08-11 | $2.89M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.10M derived: sum of 2 quarters · filed 2026-08-11 | $2.86M 10-Q · filed 2025-11-13 | $3.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.10M 10-Q · filed 2026-08-11 | $2.86M 10-Q · filed 2026-08-11 | $3.79M derived: sum of 3 quarters · filed 2026-08-11 | $4.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $825.00K 10-Q · filed 2026-05-13 | $1.69M derived: sum of 2 quarters · filed 2026-05-13 | $2.59M derived: sum of 3 quarters · filed 2026-05-13 | $3.49M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $865.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.76M derived: sum of 2 quarters · filed 2026-03-30 | $2.67M derived: sum of 3 quarters · filed 2026-03-30 | $3.53M 10-K · filed 2026-03-30 |
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-13 | $1.80M derived: sum of 2 quarters · filed 2025-11-13 | $2.66M 10-Q · filed 2025-11-13 | $3.63M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $900.00K 10-Q · filed 2025-08-12 | $1.81M 10-Q · filed 2025-08-12 | $2.73M derived: sum of 3 quarters · filed 2025-08-12 | $3.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $943.00K 10-Q · filed 2025-05-14 | $1.83M derived: sum of 2 quarters · filed 2025-05-14 | $2.73M derived: sum of 3 quarters · filed 2025-05-14 | $3.63M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $892.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.79M derived: sum of 2 quarters · filed 2025-03-20 | $2.69M derived: sum of 3 quarters · filed 2025-03-20 | $3.49M 10-K · filed 2025-03-20 |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-07 | $1.80M derived: sum of 2 quarters · filed 2024-11-07 | $2.60M 10-Q · filed 2024-11-07 | $3.27M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-08 | $1.71M 10-Q · filed 2024-08-08 | $2.37M derived: sum of 3 quarters · filed 2024-08-08 | $3.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $837.00K 10-Q · filed 2024-05-09 | $1.47M derived: sum of 2 quarters · filed 2024-05-09 | $2.37M derived: sum of 3 quarters · filed 2024-05-09 | $2.97M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $632.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $1.53M derived: sum of 2 quarters · filed 2024-03-20 | $2.13M derived: sum of 3 quarters · filed 2024-03-20 | $2.52M 10-K · filed 2024-03-20 |
| 2022-09-30 | $900.00K 10-Q · filed 2023-11-07 | $1.50M derived: sum of 2 quarters · filed 2023-11-07 | $1.89M 10-Q · filed 2023-11-07 | $2.32M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-10 | $1.00M 10-Q · filed 2023-08-10 | $1.42M derived: sum of 3 quarters · filed 2023-08-10 | $1.72M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $426.00K 10-Q · filed 2023-05-11 | $821.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.12M derived: sum of 3 quarters · filed 2023-05-11 | $1.52M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $395.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $695.00K derived: sum of 2 quarters · filed 2023-03-23 | $1.09M derived: sum of 3 quarters · filed 2023-03-23 | $1.43M 10-K · filed 2023-03-23 |
| 2021-09-30 | $300.00K 10-Q · filed 2022-11-10 | $700.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.04M 10-Q · filed 2022-11-10 | $1.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-11 | $665.00K 10-Q · filed 2022-08-11 | $953.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.15M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $311.00K 10-Q · filed 2022-05-12 | $553.00K derived: sum of 2 quarters · filed 2022-05-12 | $753.00K derived: sum of 3 quarters · filed 2022-05-12 | $853.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $442.00K derived: sum of 2 quarters · filed 2022-03-14 | $542.00K derived: sum of 3 quarters · filed 2022-03-14 | $605.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-10 | $300.00K derived: sum of 2 quarters · filed 2021-11-10 | $363.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-09 | $171.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $66.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |